22. Maroko PR, Radvany P, Braunwald E, Hale SL: Reduction of infarct size by oxygen inhalation following acute coronary occlusion. mill exercise testing. Our initial experience with NTG spray has been presented in preliminary form.8
Methods
PatientsTwenty patients (17 males and three females), mean age 61 years (range 50-74 years), with stable, exercise-induced angina pectoris participated in this trial. Their history of angina ranged from 6 months to 12 years (average 44 months). All patients had angiographically demonstrable coronary artery disease, and had at least 70% narrowing of luminal diameter in at least one major coronary artery. Ten patients had had a myocardial infarction at least 6 months before the study. Five patients had undergone coronary artery bypass graft surgery but continued to have stable angina. None of the patients were hypertensive or had clinical or radiologic evidence of heart failure. All patients had undergone treadmill exercise testing within 6 months before the study; treadmill exercise-induced angina and ischemic ST depression of 1.0 mm or more lasting at least 0.08 second occurred in each patient. All In the sitting position 1 minute after NTG spray, there was no significant change in heart rate compared with control. However, 2 minutes after administration of NTG spray in the standing position, mean heart rate increased significantly (p < 0.01). Placebo spray did not increase heart rate either in the sitting or standing position. Systolic blood pressure declined significantly after NTG spray in the sitting and standing positions (p < 0.001). Placebo spray had no significant effect on systolic blood pressure in the standing position.Effect on Exercise-induced Angina and Exercise Tolerance NTG spray relieved symptoms in all 20 patients. The onset of angina was delayed by a mean of 100 ± 64 seconds (p < 0.001) in 13 patients and pain was totally prevented in seven patients. Placebo delayed the onset of angina in 11 patients, but the magnitude of the delay was not significant (17 + 39 seconds); placebo prevented angina in only one patient.Exercise tolerance as assessed by maximal exercise duration improved significantly after NTG. NTG spray extended exercise duration 31%, from 321 + 97 to 420 + 111 seconds (p < 0.001). In contrast, there was no significant alteration after placebo compared with control (300 ± 97 vs 312 + 97 seconds).Estimated maximal total body oxygen consumption (VO2 max) at peak exercise increased from 24.1 + 3.8 to 27.6 ± 4.9 ml/kg/min (p < 0.001) after NTG spray, but did not significantly change after placebo (22.9 + 3.7 to 23.4 + 3.8 ml/kg/min).
Hemodynamic Data at Maximal ExerciseMaximal heart rate increased in all patients after *Chest pain scale: 0 = no pain; 1 + = mild pain; 2 + = moderate pain; 3 + = moderately severe pain (or equivalent to that which usually necessitated discontinuation of activity); 4 + = very severe pain equivalent to the most severe pain the patient had experienced. Measurements in the sitting position were taken 1 minute after ad...